MAPLE GROVE, Minn., Oct. 2, 2019 /PRNewswire/ -- Upsher-Smith Laboratories, LLC (Upsher-Smith) today announced the launch of Tosymra ™ (sumatriptan) Nasal Spray, 10 mg for the acute treatment of ...
Tosymra (sumatriptan) is a brand-name drug that’s prescribed to treat migraine with or without aura in adults. Tosymra comes as a nasal spray that’s used when needed to manage a migraine episode.
Sumatriptan 5mg, 20mg; per spray. The vascular 5-HT 1 receptor subtype to which sumatriptan binds selectively, and through which it presumably exerts its antimigrainous effect, is present on cranial ...
Tosymra Nasal Spray 10 mg is a Proprietary Acute Migraine Treatment Approved Under the 505(b)2 Pathway Based on Bioequivalence to Imitrex (sumatriptan) Injection 4 mg GlaxoSmithKline Recently Notified ...
Lannett Company, Inc. (NYSE: LCI) today announced that it has received approval from the U.S. Food and Drug Administration (FDA) of its Abbreviated New Drug Application (ANDA) for Sumatriptan Nasal ...
Tosymra (sumatriptan) is a prescription drug used to treat migraine. The drug comes as a nasal spray. You usually use a single dose, which may be repeated two more times in a 24-hour period if needed.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback